Bioactivation of chemicals by cytochromes P450

• Autorzy: Ioannides C.
• Języki publikacji: EN

Abstrakty

EN

Most chemical carcinogens require metabolism to generate highly reactive intermediates that manifest their carcinogenicity following covalent interaction with DNA. This bioactivation process is catalysed chiefly by cytochromes P450, a superfamily of enzymes localised primarily in the liver. The carcinogenic activity of a chemical is largely dependent on the profile and concentration of cytochromes P450 at the time of exposure.

Słowa kluczowe

EN

cytochrome P450; xenobiotics; carcinogenesis; metabolic activation

PL

cytochrom P450; ksenobiotyk; kancerogeneza; aktywacja metaboliczna

• Wydawca: University of Warmia and Mazury in Olsztyn, Poland
• Czasopismo: Environmental Biotechnology
• Rocznik: 2007
• Tom: Vol. 3, No. 1
• Strony: 1--9
• Opis fizyczny: Bibliogr. 70 poz., rys., tab.

Twórcy

autor

Ioannides C.

• Molecular Toxicology Group, School of Biomedical and Molecular Sciences, University of Surrey, Guildford, Surrey, GU2 7XH, UK, Tel.: [phone], Fax: [phone],

Bibliografia

• Anttila, S., E. Hietanen, H. Vainio, A-M. Camus, H.V. Gelboin, S.S Park, L. Heikkila, A. Karjalainen, H. Bartsch. 1991. Smoking and peripheral type of cancer are related to high levels of pulmonary cytochrome P450IA in lung cancer patients. International Journal of Cancer 47: 681-685.
• Aoyama, T., S. Yamano, P.S. Guzelian, H.V. Gelboin, F.J. Gonzalez. 1990. Five of 12 forms of vaccinia virus-expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proceedings of the National Academy of Sciences USA 87: 4790-4793.
• Astrom, A., J.W. De Pierre. 1985. Metabolism of 2-acetylaminofluorene by eight different forms of cytochrome P-450 isolated from rat liver. Carcinogenesis 6: 113-120.
• Ayrton, A.D., M. McFarlane, R. Walker, S. Neville, C. Ioannides. 1990a. The induction of P450 I proteins by aromatic amines may be related to their carcinogenic potential. Carcinogenesis 11: 803-809.
• Ayrton, A.D., M. McFarlane, R. Walker, S. Neville, M.M. Coombs, C. Ioannides. 1990b. Induction of the P450 I family of proteins by polycyclic aromatic hydrocarbons. Possible relationship to their carcinogenicity. Toxicology 60: 173-186.
• Bartsch, H., M. Castegnaro, M. Rojas, A-M. Camus, K. Alexandrov, M. Lang. 1992. Expression of pulmonary cytochrome P4501A1 and carcinogen adduct formation in high risk subjects for tobacco--related lung cancer. Toxicology Letters 64/65: 477-483.
• Bhattacharyya, K.K., P.B. Brake, S.E. Eltom, S.A. Otto, C.R. Jefcoate. 1995. Identification of a rat adrenal cytochrome P450 active in polycyclic-hydrocarbon metabolism as rat CYP1B1- demonstration of a unique tissue-specific pattern on hormonal and aryl-hydrocarbon receptor-linked regulation. Journal of Biological Chemistry 270: 11595-11602.
• Buters, J.T.M., S. Sakai, T. Richter, T. Pineau, D.L. Alexander, U. Savas, J. Doehmer, J.M. Ward, C.R. Jefcoate, F.J. Gonzalez. 1999. Cytochrome P450 CYP1B1 determines susceptibility to 7,12-dimethylbenz[a]anthracene-induced lymphomas. Proceedings of the National Academy of Sciences USA 96: 1977-1982.
• Cheung, Y-L., S.M. Puddicombe, T.J.B. Gray, C. Ioannides. 1994. Mutagenicity and CYP1A induction by azobenzenes correlates with their carcinogenicity. Carcinogenesis 15: 1257-1263.
• Cheung, Y-L., J. Snelling, N.N.D. Mohammed, T.J.B. Gray, C. Ioannides. 1996. Interaction with the aromatic hydrocarbon receptor, CYP1A induction, and mutagenicity of a series of diaminotoluenes: implications for their carcinogenicity. Toxicology and Applied Pharmacology 139: 203-211.
• Cheung, Y-L., D.F.V. Lewis, T.I. Ridd, T.J.B. Gray, C. Ioannides. 1997. Diaminonaphthalenes and related aminocompounds: Mutagenicity, CYP1A induction and interaction with the Ah receptor. Toxicology 118: 115-127.
• Christou, M., U. Savas, S. Schroeder, X. Shen, T. Thompson, M.N. Gould, C.R. Jefcoate. 1995. Cytochromes CYP1A1 and CYP1B1 in the rat mammary gland: Cell-specific expression and regulation by polycyclic aromatic hydrocarbons and hormones. Molecular and Cellular Endocrinology 115: 41-50.
• Code, E.L., C.L. Crespi, B.W. Penman, F.J. Gonzalez, T.K.H. Chang, D.J. Waxman. 1997. Human cytochrome P4502B6 - Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metabolism and Disposition 25: 985-993.
• Danielson, P.B. 2002. The cytochrome P450 superfamily: Biochemistry, evolution and drug metabolism in humans. Current Drug Metabolism 3: 561-597.
• Duescher, R.J., A.A. Elfarra. 1994. Human liver microsomes are efficient catalysts of 1,3-butadiene oxidation: evidence of major roles by cytochrome P4502A6 and 2E1. Archives of Biochemistry and Biophysics 311: 342-349.
• Gardiner, S.J, E.J. Begg. 2006. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacological Reviews 58: 521-590.
• Guengerich, F.P. 1990. Characterization of roles in human cytochrome P-450 enzymes in carcinogen metabolism. 1990. Asia Pacific Journal of Pharmacology 5: 327-345.
• Guengerich, F.P. 2002. Cytochrome P450. In: Enzyme Systems that Metabolise Drugs and Other Xenobiotics (ed. C. Ioannides), pp. 33-65. John Wiley & Sons, Chichester, UK.
• Guengerich, F.P., T. Shimada. 1991. Oxidation of toxic and carcinogenic chemical by human cytochrome P-450 enzymes. Chemical Research in Toxicology 4: 391-407.
• Hammons, G.J., F.P. Guengerich, C.C. Weis, F.A. Beland, F.F. Kadlubar. 1985. Metabolic oxidation of carcinogenic arylamines by rat, dog, and human hepatic microsomes and by purified flavin-containing and cytochrome P-450 monooxygenases. Cancer Research 45: 3578-3585.
• Hayes, C.L., D.C. Spink, B.C. Spink, J.Q. Cao, N.J. Walker, T.R. Sutter. 1996. 17-Estradiol hydroxylation catalysed by human cytochrome P4501B1. Proceedings of the National Academy of. Sciences USA 93: 9776-9781.
• Ingelman-Sundberg, M. 2005. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics Journal 5: 6-13.
• Ioannides, C. 1990. Induction of cytochrome P450 I and its influences in chemical carcinogenesis. Biochemical Society Transactions 18: 32-34.
• Ioannides, C. 1999. Effect of diet and nutrition on the expression of cytochromes P450. Xenobiotica 29: 109-154.
• Ioannides, C. (ed). 2002a. Enzyme Systems that Metabolise Drugs and Other Xenobiotics. 578 p. John Wiley & Sons, Chichester, UK.
• Ioannides, C. 2002b. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 32: 451-478.
• Ioannides, C., D.F.V. Lewis. 2004. Cytochromes P450 in the bioactivation of chemicals. Current Topics in Medicinal Chemistry 4: 1767-1788.
• Ioannides, C., D.V. Parke, 1990. The cytochrome P450 I gene family of microsomal haemoproteins and their role in the metabolic activation of chemicals. Drug Metabolism Reviews 22: 1-85.
• Ioannides, C., D.V. Parke. 1993. Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis. Drug Metabolism Reviews 25: 485-501.
• Ioannides, C., Y-L. Cheung, J. Wilson, D.F.V. Lewis, T.J.G. Gray. 1993. The mutagenicity and interactions of 2- and 4-(acetylamino)fluorene with cytochrome P450 and the aromatic hydrocarbon receptor may explain the difference in their carcinogenic potency. Chemical Research in Toxicology 6: 535-541.
• Ioannides, C., C.R. Barnett, A. Irizar, P.R. Flatt. 1996. Expression of cytochrome P450 proteins in disease. In: Cytochromes P450: Metabolic and Toxicological Aspects (ed. C. Ioannides), pp. 301-327. CRC Press Inc, Boca Raton, USA.
• Kamataki, T., K-I. Fujita, K. Nakayama, Y. Yamazaki, M. Miyamoto, N. Ariyoshi. 2002. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP. Drug Metabolism Reviews 34: 667-676.
• Kim, J.H., K.G. Stansbury, N.J. Walker, M.A. Trush, P.T. Strickland, T.R. Sutter. 1998. Metabolism of benzo[a]pyrene and benzo-[a]pyrene-7,8-diol by human cytochrome P450 1B1. Carcinogenesis 19: 1847-1853.
• Kitada, M., M. Taneda, K. Ohta, K. Nagashima, K. Itahashi, T. Kamataki. 1990. Metabolic activation of aflatoxin B1 and 2-amino-3-methylimidazo[4,5-f]quinoline by human adult and fetal livers. Cancer Research 50: 2641-2645.
• Lewis, D.F.V., C. Ioannides, D.V. Parke. 1986. Molecular dimensions of the substrate binding site of cytochrome P-448. Biochemical Pharmacology 35: 2179-2185.
• Lewis, D.F.V., C. Ioannides, D.V. Parke. 1987. Structural requirements for substrates of cytochromes P-450 and P-448. Chemico-Biological Interactions 64: 39-60.
• Lewis, D.F.V., C. Ioannides, D.V. Parke. 1993. Validation of a novel molecular orbital approach (COMPACT) for the prospective safety evaluation of chemicals by comparison with rodent carcinogenicity and Salmonella mutagenicity data evaluated by the US NCI/NTP.Mutation Research 291: 61-77.
• Liu, C., X. Zhuo, F.J. Gonzalez, X.X. Ding. 1996. Baculovirus-mediated expression and characterization of rat CYP2A3 and human CYP2A6: role in metabolic activation of nasal toxicants. Molecular Pharmacology 50: 781-788.
• McKinnon, R.A., W.M. Burgess, M.P. Hall, S.J. Roberts-Thomson, F.J. Gonzalez, M.E. McManus. 1995. Characterization of CYP3A gene subfamily expression in human gastrointestinal tissues. Gut 36: 259-267.
• Murray, G.I., M.C. Taylor, M.C.E. McFadyen, J.A. McKay, W.F. Greenlee, M.D. Burke, T.W. Melvin. 1997. Tumor-specific expression of cytochrome P-450 CYP1B1. Cancer Research. 57: 3026-3031.
• Nebert, D.W. 1989. The Ah locus: genetic differences in toxicity, cancer, mutation and birth defects. CRC Critical Reviews in Toxicology 20: 153-174.
• Ogawa, K., H. Tsuda, T. Shirai, T. Ogiso, K. Wakabayashi, D.W. Dalgard, U.P. Thorgeirsson, S.S. Thorgeirsson, R.H. Adamson, T. Sugimura. 1999. Lack of carcinogenicity of 2-amino-3,8-dimethylimidazo[4,5-f]-quinoxaline (MeIQx) in cynomolgus monkeys. Japanese Journal of Cancer Research 90: 622-628.
• Rendic, S., F. Di Carlo. 1997. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism Reviews 29: 413-580.
• Ronis, M.J.J., K.O. Lindros, M. Ingelman-Sundberg. 1996. The CYP2E subfamily. In: Cytochromes P450: Metabolic and Toxicological Aspects (ed. C. Ioannides), pp. 211-239. CRC Press Inc, Boca Raton, USA.
• Roy, D., A. Bernhardt, H.W. Strobel, J.G. Liehr. 1992. Catalysis of the oxidation of steroid and stilbene estrogens to estrogen quinone metabolites by the -naphthoflavone-inducible cytochrome P450IA family. Archives of Biochemistry and Biophysics 296: 450-456.
• Ryan, D.E., W. Levin. 1990. Purification and characterization of hepatic cytochrome P-450. Pharmacology Therapeutics 45: 153-239.
• Seeff, L.B., B.A. Cuccherini, H.J. Zimmerman, E. Adler, S.B. Benjamin, 1986. Acetaminophen toxicity in the alcoholic. A therapeutic misadventure. Annals of Internal Medicine 104: 399-404.
• Shimada, T., S-I. Nakamura, S. Imaoka, Y. Funae. 1987. Genotoxic and mutagenic activation of aflatoxin B1 by constitutive forms of cytochrome P-450 in rat liver microsomes. Toxicology and Applied Pharmacology 91: 13-21.
• Shimada, T., M. Iwasaki, M.V. Martin, F.P. Guengerich. 1989. Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA1535/pSK1002. Cancer Research 49: 3218-3228.
• Shimada, T., C.L. Hayes, H. Yamazaki, S. Amin, S.S. Hecht, F.P. Guengerich, T.R. Sutter, 1996. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Research 56: 2979-2984.
• Shimada, T., K. Inoue, Y. Suzuki, T. Kawai, E. Azuma, T. Nakajima, M. Shindo, K. Kurose, A. Sugie, Y. Yamagishi, Y. Fujii-Kuriyama, M. Hashimoto. 2002. Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice. Carcinogenesis 23: 1199-1207.
• Shimizu, Y., Nakatsuru, M. Ichinose, Y. Takahashi, H. Kume, J. Mimura, Y. Fujii-Kuriyama, T. Ishikawa. 2000. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proceedings of the National Academy of Sciences USA 97: 779-782.
• Shou, M., K.W. Krausz, F.J. Gonzalez, H.V. Gelboin. 1996. Metabolic activation of the potent carcinogen dibenzo[a]anthracene by cDNA-expressed human cytochromes P450. Archives of Biochemistry and Biophysics 328: 201-207.
• Shu, L., P.F. Hollenberg. 1997. Alkylation of cellular macromolecules and target specificity of carcinogenic nitrosodialkylamines: metabolic activation by cytochromes P450 2B1 and 2E1. Carcinogenesis 18: 801-810.
• Smith, T.J., Z. Guo, F.J. Gonzalez, F.P. Guengerich, G.D. Stoner, C.S. Yang. 1992. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung and liver microsomes and in human cells containing cDNA-expressed cytochromes P-450. Cancer Research 52: 1757-1763.
• Sogawa, K., Y. Fujii-Kuriyama Y. 1997. Ah receptor, a novel ligand-activated transcription factor. Journal of Biochemistry 122: 1075-1079.
• Sohn, O.S., E.S. Fiala, S.P. Requeijo, J.H. Weisburger, F.J. Gonzalez. 2001. Differential effects of CYP2E1 status on the metabolic activation of the colon carcinogens azoxymethane and methylazoxymethanol. Cancer Research 61: 8435-8440.
• Su, T., Z. Bao, Q-Y. Zhang, T.J. Smith, J-Y. Hong, X. Ding. 2000. Human cytochrome P450 CYP2A3: Predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Research 60: 5074-5079.
• Valentine, J.L., S.S.T. Lee, M.J. Seaton, B. Asgharian, G. Farris, J.C. Corton, F.J. Gonzalez, M. Medinsky. 1996. Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression. Toxicology Applied Pharmacology 14: 205-213.
• Wall, K.L., W. Gao, J.M. TeKoppele, G.Y. Kwei, F.C. Kauffman, R.G. Thurman. 1991. The liver plays a central role in the mechanism of chemical carcinogenesis due to polycyclic aromatic hydrocarbons. Carcinogenesis 12: 783-786.
• Wong, F.W-Y., W-Y. Chan, S.S-T. Lee. 1998. Resistance to carbon tetrachloride-induced hepatotoxicity in mice which lack CYP2E1 expression. Toxicology Applied Pharmacology 153: 109-118.
• Xu, G., C.Y.-T. Li, A.N.-T. Kong. 2005. Induction of Phase I, II and III drug metabolism/transport by xenobiotics. Archives of Pharmacological Research 28: 249-268.
• Yamazaki, H., H. Inui, C.H. Yun, M. Mimura, F.P. Guengerich, T. Shimada. 1992. Cytochrome P4502E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13: 1789-1794.
• Yamazaki, H., Y. Inui, S.A. Wrighton, F.P. Guengerich, T. Shimada. 1995. Procarcinogen activation by cytochrome-p450 3a4 and 3a5 expressed in Escherichia coli and by human liver-microsomes. Carcinogenesis 16: 2167-2170.
• Yamazaki, H., P.M. Shaw, F.P. Guengerich, T. Shimada. 1998. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chemical Research in Toxicology 11: 659-665.
• Yano, M., T. Higashi, S. Kano, N. Tateishi, Y. Kido, M. Takesada, K. Higashi, Y. Sakamoto. 1989. Decreased activation of carcinogens in the liver of carcinogen-resistant rats. Cancer Research 49: 5352-5375.
• Yoshimoto, F., S. Masuda, T. Higashi, T. Nishii, A. Takamisawa, N. Tateishi, Y. Sakamoto. 1985. Comparison of drug metabolizing activities in the livers of carcinogen-sensitive parent drugs and carcinogen-resistant descendants. Cancer Research 45: 6155-6159.
• Zenser, T.V., V.M. Lakshmi, B.B. Davis. 1999. Human and Escherichia coli β-glucuronidase hydrolysis of benzidine and 4-aminobiphenyl, and their hydroxymetabolites. Drug Metabolism and Disposition 27: 1064-1067.
• Zhou, S., S.Y. Chan, B.C. Goh, E. Chan, W. Duan, M. Huag, H.L. McLeod. 2005. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clinical Pharmacokinetics 44: 279-304.
• Zimmerman, H.J., W.C. Maddrey. 1995. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: Analysis of instances of therapeutic misadventure. Hepatology 22: 767-773.